## SYNTHESIS AND BIOLOGICAL ACTIVITY OF A 5,6-SUBSTITUTED TELEOCIDIN

Robert R. Webb II,\* and Michael C. Venuti
Bioorganic Chemistry Department, Genentech, Inc., 460 Pt. San Bruno Blvd.,
South San Francisco, California 94080

(Received 3 March 1992)

**Abstract.** The synthesis of 5,6-substituted teleocidin analogue 3 is reported. Reduction of oxime 7 (obtained from indole 6) gave diastereometric amines 8 and 9 which were cyclized to give esters 10 and 11, respectively. Reduction of 10 yielded teleocidin analogue 3, which displayed activity comparable to (-)-indolactam V in a standard  ${}^{3}[H]$ -phorbol-dibutyrate binding assay.

The teleocidins continue to be of interest, not only as tumor promoters and activators of Protein Kinase C (PKC),<sup>1,2</sup> but also as departure points for the design of effective inhibitors. The search for inhibitors has intensified,<sup>3</sup> due in large part to a recent report implicating PKC in *tat* trans-activation, a process believed to be crucial for HIV infectivity.<sup>4</sup> One of the issues remaining to be resolved with regard to understanding the mode of action of the teleocidin tumor promoters is the function of the N-methyl group at the 4-position of the indole nucleus. In the course of preparing teleocidin 2 (an analogue of teleocidin B-4 (1)),<sup>5</sup> we became interested in the des-methyl isomeric analogue 3. While molecular models of 3 showed severe steric crowding about the nitrogen at the 4-position, which convinced us that the N-methyl compound would be impossible to prepare, these same models showed steric interactions between the gem-dimethyl group at position 5 and the isopropyl group at position 12 that might produce a conformation of the 9-membered ring lactam similar to that found in the (N-methylated) teleocidins.<sup>1</sup> As very few 5-substituted and 6-substituted indolactams have been reported,<sup>6</sup> and since the indole needed for the synthesis of 3 was readily available, we sought to prepare the des-methyl compound 3 and evaluate it's biological activity.

The chemistry used to prepare these compounds follows literature precedent .5,9 Indole 45 was reduced with iron in acetic acid/ethanol<sup>7</sup> to give the air-sensitive amino indole 5 in 66% yield.<sup>8</sup>

This amine was alkylated with the triflate of (*R*)-2-hydroxyvaleric acid benzyl ester<sup>9</sup> in refluxing dichloroethane containing 2,6-lutidine to give the N-valyl indole 6 in 63% yield.<sup>10</sup> Alkylation at the 3-position of indole 6 was accomplished in CH<sub>2</sub>Cl<sub>2</sub>/K<sub>2</sub>CO<sub>3</sub> with ethyl(3-bromo-2-oximido)-propionate (Gilchrist's reagent<sup>11</sup>) giving oxime 7 in 50% yield.<sup>12</sup> Reduction of oxime 7 (Al(Hg)) furnished a 3:1 mixture of the diastereomeric amines 8 and 9 (90% total).<sup>13</sup> These amines were easily separated by flash chromatography, and subjected to hydrogenolysis of the benzyl ester and BOP coupling to accomplish the closure of the 9-membered rings.<sup>5,9</sup> Ester 10<sup>11</sup> (derived from amine 8 in 55% yield) gave two conformers as displayed in the <sup>1</sup>H NMR, with the major conformer dominating in the ratio of 3 to 1. This ester was reduced with LiBH<sub>4</sub> in tetrahydrofuran giving alcohol 3<sup>12</sup> in 90% yield, which was characterized by the presence of "twist"/"sofa" conformers<sup>13</sup> as evidenced in the <sup>1</sup>H NMR (1:1 ratio).

R
H, N 
$$CO_2Bn$$
R
 $A: R = NO_2$ 
 $5: R = NH_2$ 
 $A: R = NO_2$ 
 $5: R = NH_2$ 
 $A: R = NO_2$ 
 $A: R = N$ 

As demonstrated by the teleocidins and IL-V, the methylene protons at position 8 displayed a significant nOe with the methine proton at position 12 in the ROESY spectrum. Ester 11 (derived from amine 9), on the other hand, appeared as a single compound by <sup>1</sup>H NMR, and was reduced (LiBH<sub>4</sub>/THF)<sup>5</sup> to give alcohol 12.

Even though it lacks both substitution at the 7 position of the indole and an N-methyl group, teleocidin 3 demonstrated a level of binding to PKC comparable to that of (-)-indolactam V in a standard <sup>3</sup>[H]-PDBU assay (IC<sub>50</sub> of 400nM vs 150nM for (-)-ILV; des-methyl-(-)-ILV proved inactive in this assay). <sup>17</sup> Accordingly, teleocidin 12 showed no binding activity at all, even at concentrations of 0.01 mM. <sup>17</sup> This level of potency is surprising since generally it has been assumed that the N-methyl group present in the teleocidins is required for tumor promoting activity. It is also of interest that other 5-substituted indolactams *possessing an N-methyl group*, showed reduced activity from that of (-)-ILV. <sup>16</sup> The above observations would seem to confirm that the stereochemistry at position 9 is the single most crucial structural aspect of these compounds, consistent with literature observations. <sup>16</sup> It would appear that the presence or absence of an N-methyl group and substitution at positions 5 and 6 have mixed effects on activity.

**Acknowledgement**. The authors thank Dr. Thomas Gadek for his assistance in obtaining 2D NMR spectra.

## References

- 1. Fujiki, H.; Sugimura, T. Adv. Cancer Res. 1987, 49, 223.
- 2. Kozikowski, A.P.; Shum, P.W.; Basu, A.; Lazo, J.S. J. Med. Chem. 1991, 34(8), 2420-
- Davis, P.D.; Hill, C.H.; Lawton, G.; Nixon, J.S.; Wilkinson, S.E. Hurst, S.A.; Keech, E.; Turner, S.E. J. Med. Chem. 1992, 35(1), 177-184.
- 4. Jakobovits, A.; Rosenthal, A.; Capon, D.J. EMBO J. 1990, 9, 1165-1170.
- 5. Webb, R.R.; Venuti, M.C.; Eigenbrot, C. J. Org. Chem. 1991, 56, 4706.
- 6. Irie, K.; Koshimizu, K. Mem. Coll. Agric., Kyoto Univ. 1988, 132, 1.
- 7. Krolski, M.E.; Renaldo, A.F.; Rudisill, D.E.; Stille, J.K. J. Org. Chem. 1988, 53, 1170.
- (5): mp. 186-187°C (CH<sub>2</sub>Cl<sub>2</sub>/hexane); <sup>1</sup>H NMR δ8.19(brs, 1H, ArNHCH=), 7.08(t, J=3Hz, 1H, ArNHCH), 6.42(s, 1H, Ar), 6.39(dd, J=2Hz, 1H, ArCH=CH), 3.78(brs, 2H, exch., ArNH<sub>2</sub>), 1.75(m, complex, 2H, ArC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>), 1.68(m, complex, 2H, ArC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>), 1.44(s, 6H, ArC(CH<sub>3</sub>)<sub>2</sub>), 1.29(s, 6H, ArC(CH<sub>3</sub>)<sub>2</sub>); Anal. (C<sub>1</sub>6H<sub>2</sub>2N<sub>2</sub>) C, H, N.
- 9. Kogan, T.P.; Somers, T.C.; Venuti, M.C. Tetrahedron 1990, 6623.
- 10. **(6)**: <sup>1</sup>H NMR δ8.20(brs, 1H, NH), 7.27(m, 5H, ArH), 7.04(t, J=3Hz, 1H, ArNHCH=), 6.43(m, 1H, NCH=), 6.25(s, 1H, ArH), 5.16(B part, ABqd, J=1, 12Hz, 1H, ArCH2), 5.07(B part, ABq, J=12Hz, 1H, ArCH2), 4.02(d, J=6Hz, 1H, HNCH(ipr)), 4.04(t, J=6Hz, 1H, CH(ipr)CO<sub>2</sub>Bn), 2.19(sextet, J=6Hz, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.68(m, complex, 4H, CH<sub>2</sub>CH<sub>2</sub>(CH<sub>3</sub>)<sub>2</sub>), 1.42(s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.28(s, 3H, C(CH<sub>3</sub>)<sub>2</sub>), 1.23(s, 3H, C(CH<sub>3</sub>)<sub>2</sub>), 1.09(dd, J=1.5, 6Hz, 3H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.03(dd, J=1.5, 6Hz, 3H, CH(CH<sub>3</sub>)<sub>2</sub>); high res MS (C<sub>2</sub>8H<sub>3</sub>6N<sub>2</sub>O<sub>2</sub>) 432.2776; found 432.2811.
- 11. Gilchrist, T.L.; Lingham, D.A.; Roberts, T.G. J. Chem. Soc.Chem. Commun. 1979, 1089.
- 12. **(7)**: <sup>1</sup>H NMR δ9.38(brs, 1H, exch., NO<u>H</u>), 7.94(brs, 1H, not exch., ArN<u>H</u>CH=C), 7.22(m, 5H, CH<sub>2</sub>Ar<u>H</u>), 6.86(d, J=1Hz, 1H, ArNHC<u>H</u>=), 6.15(s, 1H, Ar<u>H</u>), 5.48(br s, 1H, exch., ArN<u>H</u>CH(ipr)), 5.05(ABq, J=12Hz, 2H, C<u>H</u>2Ar), 4.34(B part, ABq, J=12Hz, 1H, C<u>H</u>2C(=NOH)CO<sub>2</sub>Et), 4.18(ABq, J=6Hz, OC<u>H</u>2CH<sub>3</sub>), 4.12(A part, ABq, J=12Hz, 1H, C<u>H</u>2C(=NOH)CO<sub>2</sub>Et), 3.82(d, J=6Hz, 1H,

- NCH(ipr)CO<sub>2</sub>Bn), 2.10(sextet, J=6Hz, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.62(m, complex, 2H, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>), 1.54(m, complex, 2H, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>), 1.31(s, 6H, C(CH<sub>3</sub>)<sub>2</sub>), 1.20(t, J=6Hz, 3H, CH<sub>3</sub>CH<sub>2</sub>O), 1.17(s, 3H, (CH<sub>3</sub>)<sub>2</sub>C), 1.10(s, 3H, C(CH<sub>3</sub>)<sub>2</sub>), 1.05(d, J=6Hz, 3H, CH(CH<sub>3</sub>)<sub>2</sub>), 0.95(d, J=6Hz, 3H, CH(CH<sub>3</sub>)<sub>2</sub>); high res MS(C<sub>31</sub>H<sub>43</sub>N<sub>3</sub>O<sub>5</sub>) 561.3202, found 561.3200.
- 13. **(8)**: mp 100-102°C: <sup>1</sup>H NMR δ8.05(s, 1H, N<u>H</u>), 7.28(m, complex, 5H, Ar<u>H</u>), 6.87(d, J=2.5Hz, ArNHC<u>H</u>=), 6.20(br s, 1H, exch., N<u>H</u>), 5.12(ABq, J=12Hz, 2H, C<u>H</u>2Bn), 4.22(ABqd, J=3, 6Hz, 2H, OC<u>H</u>2CH3), 3.98(m, 1H, NHC<u>H</u>(ipr)CO<sub>2</sub>Bn), 3.86(dd, J=3, 9Hz, 1H, H2NC<u>H</u>CO<sub>2</sub>Et), 3.47(B part, ABqd, J=3, 15Hz, 1H, C<u>H</u>2CH(NH2)CO<sub>2</sub>Et), 3.00(A part, ABqd, J=9, 15Hz, 1H, C<u>H</u>2(NH2)CO<sub>2</sub>Et), 2.22(sextet, J=6Hz, 1H, C<u>H</u>(CH3)2), 1.71(m, 2H, C(CH3)2C<u>H</u>2), 1.66(m, C(CH3)2C<u>H</u>2), 1.43(s, 6H, C(C<u>H</u>3)2), 1.28(s, 3H, C(C<u>H</u>3)2), overlapping 1.28(t, J=6Hz, 3H, OCH<sub>2</sub>C<u>H</u>3), 1.20(s, 3H, C(C<u>H</u>3)2), 1.12(d, J=6Hz, 3H, CH(C<u>H</u>3)2), 1.05(d, J=6Hz, 3H, CH(C<u>H</u>3)2); Anal (C33H45N3O4) C, H, N.
- 14. **(10)**: <sup>1</sup>H NMR, major conformer (ratio major/minor=3:1): δ8.18(br s, 1H, indole-ArNH), 6.93(s, 1H, ArH), 6.84(d, J=3Hz, 1H, ArNHCH=), 5.46(B part, ABq, J=12Hz, 1H, CH2CH(NH)), 5.11(A part, ABq(d), J=3, 12Hz, 1H, CH2CH(NH)), 4.16(m, 2H, OCH2CH3), 3.45(dd, J=6, 12Hz, 1H, HNCH(ipr)CO), 2.96(br s, 1H, ArNH), 2.79(d, J=12Hz, 1H, CONHCHCO2Et), 2.25(m, complex, 1H, CH(CH3)2), 1.72(m, complex, 4H, CH2CH2C(CH3)2), 1.46 and 1.44(s, 3H each, C(CH3)2), 1.37(d, J=6Hz, 3H, CH(CH3)2), 1.32(s, 6H, C(CH3)2), 1.28(t, J=6Hz, 3H, OCH2CH3), 0.98(d, J=6Hz, 3H, CH(CH3)2); <sup>13</sup>C NMR(major conformer) δ174.95(CO2Et), 170.81(CONH), 140.28, 139.60, 136.33, 124.63, 124.18, 123.26, 118.78(Ar), 107.49, 75.54 (OCH2CH3), 1.13(HNCHCO2Et), 57.80(CH2CH(NH)CO2Et), 37.73 and 35.07(C(CH3)2), 34.19 and 33.37(CH2CH2CH2C(CH3)2), 32.10, 32.02, 28.64 and 28.56(C(CH3)2), 27.86(CH(CH3)2), 19.79 and 19.58(CH(CH3)2), 14.35(OCH2CH3); MS(EI) *m/e* (relative intensity, %) 439.4 (100, M+); high res MS(C26H37N3O3) 439.2834, found 439.2857.
- 15. **(3)**: mp >240°C(dec.); <sup>1</sup>H NMR twist conformer (ratio twist/sofa=1.5:1): δ8.09(br s, 1H, N<u>H</u>), 6.85(d, J=3Hz, 1H, NH-C<u>H</u>), 6.62(s, 1H, Ar<u>H</u>), 6.38(d, J=9Hz, 1H, CON<u>H</u>), 5.39(br s, 1H, NHC<u>H</u>CH<sub>2</sub>OH), 3.74(dd, J=4, 12Hz, 1H, CH<sub>2</sub>OH), 3.55(m, overlapping sofa, 1H, C<u>H</u><sub>2</sub>OH), 2.93(q, overlapping sofa, J=9Hz, 2H, CH=CC<u>H</u><sub>2</sub>), 2.76(d, J=12Hz, 1H, NHC<u>H</u>CO), 2.27(m, overlapping sofa, 1H, (CH<sub>3</sub>)<sub>2</sub>C<u>H</u>), 1.65(m, 4H, (CH<sub>3</sub>)<sub>2</sub>CC<u>H</u><sub>2</sub>), 1.43(s, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>C), 1.41(s, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>C), 1.30(s, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>C), 1.26(s, 3H, (C<u>H</u><sub>3</sub>)C), 1.19(d, J=6Hz, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>CH), 1.03(d, J=6Hz, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>CH); sofa conformer: δ8.33(br s, 1H, N<u>H</u>), 6.96(d, J=3Hz, 1H, NH-C<u>H</u>), 6.93(s, 1H, Ar<u>H</u>), 4.97(d, J=11Hz, 1H, CON<u>H</u>), 4.43(m, 1H, NHC<u>H</u>COH), 3.56(m, overlapping twist, 1H, C<u>H</u><sub>2</sub>OH), 3.46(m, overlapping twist, 1H, C<u>H</u><sub>2</sub>OH), 3.27(dd, J=3, 9Hz, 1H, CH=CC<u>H</u><sub>2</sub>), 2.98(m, overlapping twist, 1H, CH=CC<u>H</u><sub>2</sub>), 2.79(dd, J=3, 9Hz, 1H, NHC<u>H</u>CO), 1.71(m, overlapping twist, 1H, (CH<sub>3</sub>)<sub>2</sub>CCH), 1.32(s, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>C), 1.45(s, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>C), 1.36(d, J=6Hz, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>CH), 1.32(s, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>C), 1.29(s, 3H, (C<u>H</u><sub>3</sub>)C), 0.96(d, J=6Hz, 3H, (C<u>H</u><sub>3</sub>)<sub>2</sub>CH); high res MS (C<sub>2</sub>4H<sub>3</sub>5N<sub>3</sub>O<sub>2</sub>) 397.2729, found 397.2730. Anal. (C<sub>2</sub>4H<sub>3</sub>5N<sub>3</sub>O<sub>2</sub>) C, H, N.
- 16. Endo, Y.; Shudo, K.; Itai, A.; Hasegawa, M.; Sakai, S. *Tetrahedron* **1986**, *42*(21), 5905. 17. Ashendel, C.L. *Biochem. Biophys. Acta* **1985**, *822*, 219.